Printer Friendly

Alzheimer drug will get wider testing.

The maker of the experimental Alzheimer drug tacrine (THA) won the Food and Drug Administration's okay last week to distribute the still unapproved medication more widely under the FDA's special "expanded-use" program for promising but unproven therapies.

FDA Commissioner David A. Kessler announced on the CBS show "This Morning" that Warner-Lambert Co. may provide THA in a range of escalating dosages to up to 3,000 Alzheimer's patients not enrolled in a controlled clinical trial of the drug. But Kessler cautioned that "it's very important to underline that it's only suggestive that the drug works." He added that while previous trials indicated that THA can slow memory loss among some Alzheimer patients, they also demonstrated the drug's potential for damaging patients' livers.

An FDA advisory committee declined to recommend approval of THA last March, citing the insufficiency of safety and efficacy data (SN: 3/23/91, p. 180).
COPYRIGHT 1991 Science Service, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:tacrine
Publication:Science News
Date:Dec 14, 1991
Words:148
Previous Article:Resignation tied to misconduct probe.
Next Article:Stomach bug linked to gastric cancer.
Topics:


Related Articles
Early trials of Alzheimer drug positive.
Alzheimer's drug fails panel review.
Tacrine: reversal of fortune?
Mossy memory-booster for Alzheimer's?
Sea worms and plants spur new drugs.
Alzheimer's disease: what we know now.
Highlights From the Annual Scientific Assembly: Managing the Stages of Alzheimer's Disease--new management options. (Special Feature).
New drug slows Alzheimer's. (Briefly...).
Alzheimer's drugs seem safe From MMA changes.
Experimental drug targets Alzheimer's.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters